Radiation-induced lung toxicity predictors: Retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.


Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 28 08 2019
revised: 04 11 2019
accepted: 06 11 2019
pubmed: 17 3 2020
medline: 14 5 2020
entrez: 17 3 2020
Statut: ppublish

Résumé

The main complication after hypofractionated radiotherapy for lung carcinoma is radiation-induced lung toxicity, which can be divided into radiation pneumonitis (acute toxicity, occurring within 6 months) and lung fibrosis (late toxicity, occurring after 6 months). The literature describes several predictive factors related to the patient, to the tumor (volume, central location), to the dosimetry and to biological factors. This study is a retrospective analysis of 90 patients treated with stereotactic body irradiation for stage I non-small-cell lung carcinoma between December 2010 and May 2015. Radiation pneumonitis was observed in 61.5% of the patients who were mainly asymptomatic (34%). Chronic obstructive pulmonary disease was not predictive of radiation pneumonitis, whereas active smoking was protective. Centrally located tumors were not more likely to result in this complication if the radiation schedule utilized adapted fractionation. In our study, no predictive factor was identified. Whereas the mean lung dose was a predictive factor in 3D radiotherapy, the lung volume irradiated at high doses seemed to be involved in the pathogenesis after hypofractionated radiotherapy. The discovery of predictive factors for radiation pneumonitis is difficult due to the rarity of this complication, especially with an 8×7.5Gy schedule. Radiation pneumonitis seems to be correlated with the volume irradiated at high doses, which is in contrast to the known knowledge about the organs in parallel. This finding leads us to raise the hypothesis that vessel damage, organs in series, occurring during hypofractionated radiotherapy could be responsible for this toxicity.

Sections du résumé

BACKGROUND BACKGROUND
The main complication after hypofractionated radiotherapy for lung carcinoma is radiation-induced lung toxicity, which can be divided into radiation pneumonitis (acute toxicity, occurring within 6 months) and lung fibrosis (late toxicity, occurring after 6 months). The literature describes several predictive factors related to the patient, to the tumor (volume, central location), to the dosimetry and to biological factors.
MATERIALS AND METHODS METHODS
This study is a retrospective analysis of 90 patients treated with stereotactic body irradiation for stage I non-small-cell lung carcinoma between December 2010 and May 2015.
RESULTS RESULTS
Radiation pneumonitis was observed in 61.5% of the patients who were mainly asymptomatic (34%). Chronic obstructive pulmonary disease was not predictive of radiation pneumonitis, whereas active smoking was protective. Centrally located tumors were not more likely to result in this complication if the radiation schedule utilized adapted fractionation. In our study, no predictive factor was identified. Whereas the mean lung dose was a predictive factor in 3D radiotherapy, the lung volume irradiated at high doses seemed to be involved in the pathogenesis after hypofractionated radiotherapy.
CONCLUSION CONCLUSIONS
The discovery of predictive factors for radiation pneumonitis is difficult due to the rarity of this complication, especially with an 8×7.5Gy schedule. Radiation pneumonitis seems to be correlated with the volume irradiated at high doses, which is in contrast to the known knowledge about the organs in parallel. This finding leads us to raise the hypothesis that vessel damage, organs in series, occurring during hypofractionated radiotherapy could be responsible for this toxicity.

Identifiants

pubmed: 32173269
pii: S1278-3218(20)30059-7
doi: 10.1016/j.canrad.2019.11.003
pii:
doi:

Substances chimiques

Angiotensin Receptor Antagonists 0
Angiotensin-Converting Enzyme Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-127

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

I Menoux (I)

Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France. Electronic address: imenoux@strasbourg.unicancer.

D Antoni (D)

Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; CNRS, IPHC UMR 7178, université de Strasbourg, Centre Paul-Strauss, institut régional de cancérologie, UNICANCER, 67000 Strasbourg, France.

C Mazzara (C)

Department of Medical Physics, Paul Strauss Center, 3, rue de la porte de l'hôpital, BP 42, 67065 Strasbourg cedex, France.

A Labani (A)

Department of Radiology, Nouvel Hôpital Civil, 1, place de l'hôpital, 67000 Strasbourg, France.

A Charloux (A)

Department of Respiratory functional explorations, nouvel hôpital civil, 1, place de l'Hôpital, 67000 Strasbourg, France.

E Quoix (E)

Department of Pneumology, nouvel hôpital civil, 1, place de l'hôpital, 67000 Strasbourg, France.

P-E Falcoz (PE)

Department of Thoracic surgery, nouvel hôpital civil, 1, place de l'hôpital, 67000 Strasbourg, France.

P Truntzer (P)

Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France.

G Noël (G)

Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; CNRS, IPHC UMR 7178, université de Strasbourg, Centre Paul-Strauss, institut régional de cancérologie, UNICANCER, 67000 Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH